Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAyrton BangoloBABehzad Amoozgar

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows IDH1 mutation predicts superior survival in acute myeloid leukemia, highlighting treatment implications.

Key Points

  • Achieving complete remission is linked to a 69% lower risk of death in older patients with ND-AML.
  • Median overall survival was 11.47 months, with significant predictors including IDH1 mutation noted.
  • Analysis of genotype data used logistic regression to ascertain survival outcomes and treatment responses.
  • Findings support the need for genetic-based prognostic tools tailored for innovative AML therapies.

Cite This Study

Bangolo et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e27ehttps://doi.org/10.1182/blood-2025-7032
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study2025
  2. 2Treatment responses and survival of newly diagnosed older or unfit patients (pts) with IDH1/2-mutated Acute Myeloid Leukemia (AML): An analysis of the MARROW consortium2025
  3. 3Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes2025
  4. 4Genetic risk model to predict outcomes for AML treated with HMA and venetoclax2025
  5. 5Prolonged venetoclax (VEN) plus hypomethylating agent (HMA) therapy in non-promyelocytic AML: A single-centre retrospective cohort study2025